ANIP— ANI PHARMACEUTICALS INC

MaterialsPharmaceuticals$1.8B mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Net Revenues	$883.37B+43.8%	$614.38B+26.2%	$486.82B+53.9%	$316.38B
Cost of sales (excluding depreciation and amortization)	$341.31B+36.4%	$250.21B+37.8%	$181.51B+30.8%	$138.78B
Research and development	$51.66B+15.9%	$44.58B+30.0%	$34.29B+53.6%	$22.32B
Selling, general, and administrative	$317.75B+27.3%	$249.64B+54.4%	$161.70B+30.4%	$124.04B
Depreciation and amortization	$91.42B+35.0%	$67.73B+13.3%	$59.79B+4.9%	$56.97B
Contingent consideration fair value adjustment	-$31.01B-4910.0%	-$619.0M-143.4%	$1.43B-62.1%	$3.76B
Loss (gain) on disposal of assets	$382.0M+107.1%	-$5.35B	$0	—
Restructuring activities	$0	$0-100.0%	$1.13B-80.1%	$5.68B
Intangible asset impairment charge	$767.0M-89.9%	$7.60B	$0-100.0%	$112.0M
Total Operating Expenses, net	$772.27B+25.8%	$613.79B+39.5%	$439.85B+25.1%	$351.67B
Operating Income	$111.09B+18922.8%	$584.0M-98.8%	$46.97B+233.1%	-$35.28B
Unrealized gain on investment in equity securities	$2.82B-55.2%	$6.31B	$0	$0
Interest expense, net	-$20.06B-14.0%	-$17.60B+34.7%	-$26.94B+4.0%	-$28.05B
Other income (expense), net	$1.93B+148.0%	-$4.03B-2436.5%	-$159.0M-123.7%	$670.0M
Loss on extinguishment of debt	$0+100.0%	-$7.47B	$0	$0
Income (Loss) Before Expense (Benefit) for Income Taxes	$95.79B+531.3%	-$22.21B-211.8%	$19.87B+131.7%	-$62.66B
Income tax expense (benefit)	$17.45B+573.0%	-$3.69B-437.6%	$1.09B+107.4%	-$14.77B
Net Income (Loss)	$78.34B+522.9%	-$18.52B-198.6%	$18.78B+139.2%	-$47.90B
Dividends on Series A Convertible Preferred Stock	-$1.16B+28.8%	-$1.63B+0.0%	-$1.63B+0.0%	-$1.63B
Net Income (Loss) Available to Common Shareholders	$77.18B+483.1%	-$20.15B-217.4%	$17.15B+134.6%	-$49.52B
Basic Income (Loss) Per Share (in dollars per share)	$3500.00+436.5%	-$1040.00-220.9%	$860.00+128.2%	-$3050.00
Diluted Income (Loss) Per Share (in dollars per share)	$3320.00+419.2%	-$1040.00-222.4%	$850.00+127.9%	-$3050.00
Basic Weighted-Average Shares Outstanding (in shares)	20.1M+3.8%	19.3M+7.3%	18.0M+10.7%	16.3M
Diluted Weighted-Average Shares Outstanding (in shares)	21.2M+9.9%	19.3M+6.2%	18.2M+11.9%	16.3M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.